^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

IFNG-L

i
Other names: IFNG , Interferon gamma
Entrez ID:
Related biomarkers:
1m
Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer (clinicaltrials.gov)
P1, N=28, Active, not recruiting, Jonsson Comprehensive Cancer Center | Recruiting --> Active, not recruiting | Trial completion date: Apr 2025 --> Apr 2026 | Trial primary completion date: Apr 2024 --> Apr 2025
Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy • Surgery • Pre-surgery
|
IFNG (Interferon, gamma)
|
IFNG-L
|
Opdivo (nivolumab) • oxaliplatin • irinotecan • leucovorin calcium • fluorouracil topical
3ms
Tumor microbiota associated with immune enrichment in breast tumor (AACR 2024)
The top five most important features contributing to the random forest model were Sulfidibacter, Prestia, Cutibacterium, Acinetobacter and Rhizobium. This study is the largest to date that characterize the tumor microbiota of an Asian cohort of breast cancers, where Sulfidibacter and Priestia, both relatively new and uncharacterized bacteria, were differentially abundant among patients with high vs low immune scores.
HER-2 (Human epidermal growth factor receptor 2) • IFNG (Interferon, gamma)
|
IFNG-L
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay
5ms
Transforming Growth Factor Beta 2 (TGFB2) and Interferon Gamma Receptor 2 (IFNGR2) mRNA Levels in the Brainstem Tumor Microenvironment (TME) Significantly Impact Overall Survival in Pediatric DMG Patients. (PubMed, Biomedicines)
Worse survival outcomes in pbDMG patients when comparing high versus low TGFB2 levels in the context of low IFNGR2 levels suggest that the abrogation of the TGFB2 mRNA expression in the immunologically cold tumor microenvironment can be used to treat pbDMG patients. Furthermore, pbDMG patients with low levels of JAK1 or STAT1 mRNA expression in combination with high levels of TGFB2 also exhibited poor OS outcomes, suggesting that the inclusion of (interferon-gamma) IFN-γ to stimulate and activate JAK1 and STAT1 in anti-tumor APC cells present the brainstem TME can enhance the effect of the TGFB2 blockade.
Journal
|
IFNG (Interferon, gamma) • JAK1 (Janus Kinase 1) • CD163 (CD163 Molecule) • CD14 (CD14 Molecule) • STAT1 (Signal Transducer And Activator Of Transcription 1) • IFNAR2 (Interferon Alpha And Beta Receptor Subunit 2) • ITGAX (Integrin Subunit Alpha X) • CD86 (CD86 Molecule) • TGFB2 (Transforming Growth Factor Beta 2)
|
IFNG-L
7ms
MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancer. (PubMed, Cell Biosci)
"miR-181a is a key factor controlling the STING pathway and driving PARPi and platinum-based drug resistance in TNBC and OvCa. The miR-181a-STING axis can be used as a potential marker for predicting PARPi responses in TNBC and OvCa tumors."
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • IFNG (Interferon, gamma) • BRCA (Breast cancer early onset) • STING (stimulator of interferon response cGAMP interactor 1) • MIR181A1 (MicroRNA 181a-1)
|
BRCA1 mutation • HER-2 negative • IFNG-L • BRCA mutation
|
HTG EdgeSeq miRNA Whole Transcriptome Assay
|
Lynparza (olaparib)
9ms
Fragmented pattern of tumor mass is related to fibroblast activation mitigating spatial interaction between tumor and immune cells (SITC 2023)
Cibersort analysis2 showed that gamma delta T cells (-52%), activated memory CD4 T cells (-50%), activated NK cells (-29%), CD8 T cells (-21%) demonstrated the most significant reductions in TFI-high. Conclusions Tumor with high fragmentation, or TFI-high is closely correlated with high fibroblast infiltration, low IFNG signature-related NK and T cells infiltration, but has minimal impact on overall densities of lymphocytes and macrophages, as well as PD-1/PD-L1 and CTLA4/CD28 axes.
PD(L)-1 Biomarker • IO biomarker • Immune cell
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CD4 (CD4 Molecule) • IL17A (Interleukin 17A) • IL1A (Interleukin 1, alpha)
|
IFNG-L
|
Lunit SCOPE IO
11ms
Interferon-gamma (IFNy) gene signature as a predictive biomarker for response in lactate dehydrogenase (LDH) low advanced melanoma patients (ESMO 2023)
Table: 1121P Conclusions Our results suggest that the IFNg-signature could become a biomarker for treatment decisions in LDH low patients directing towards anti-PD1 monotherapy (in IFNg high patients) versus combination therapy, with either anti-LAG3 or anti-CTLA-4 in IFNg low patients. However, confirmation in larger cohorts and in other combination therapies is needed.
Clinical • Gene Signature • PD(L)-1 Biomarker • IO biomarker • Metastases
|
BRAF (B-raf proto-oncogene) • IFNG (Interferon, gamma)
|
BRAF wild-type • IFNG-L • LDH-L • IFNG elevation
1year
Conserved and cell type-specific transcriptional responses to IFN-γ in the ventral midbrain. (PubMed, Brain Behav Immun)
To determine if neurons respond to in a cell-autonomous manner, we produced mutant mice with a deletion of the IFN-γ-binding domain of IFNGR1 only in dopaminergic neurons, which resulted in a complete loss of dopaminergic neuronal response to IFN-γ. Our results demonstrate that neurons can respond to IFN-γ in a cell-autonomous manner by upregulating MHC-I and its related genes in vivo, although the expression level is low compared to oligodendrocytes, astrocytes, and microglia.
Journal
|
IFNG (Interferon, gamma) • IFNGR1 (Interferon Gamma Receptor 1)
|
IFNG-L • MHC-II expression
1year
Leveraging patient-derived renal cell carcinoma organoids to enrich tumor-reactive T cells and identify novel immune checkpoints (AUA 2023)
PDO model intra-tumoral and inter-patient heterogeneity in the tumor-immune phenome and IFNg responsivity. Our paired autologous PDOT biobank enables patient-specific identification of targetable immune checkpoints and PDOT co-cultures enable characterization of patient-specific anti-tumor response to rationally design ICI combination therapies that augment anti-tumor T cell responses in RCC.
Clinical • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma)
|
IFNG-L
over1year
Clever-1/PD-L1 ratio predicts response to Bexmarilimab, a novel macrophage-guided immunotherapy, in immune deprived cancers (AACR 2023)
PD-L1/Clever-1 IHC staining ratio may be used to predict bexmarilimab responding patients. These patients have a low PD-L1 staining and low IFNg levels as reported previously, and are often refractory to checkpoint inhibitors and other T cell activating agents. Bexmarilimab provides a novel therapy option for a tumor group that is otherwise poorly responsive to immune therapies.
PD-L1 (Programmed death ligand 1) • IFNG (Interferon, gamma) • AVEN (Apoptosis And Caspase Activation Inhibitor)
|
IFNG-L • PD-L1-L
|
PD-L1 IHC 22C3 pharmDx
|
Clevegen (bexmarilimab)
over1year
CRISPR and drug screens identify ERK as the mediator of IFNg-induced melanoma growth inhibition (AACR 2023)
In live imaging experiments, we found that blocking ERK activity with the ERK inhibitor Ulixertinib blocks the induction of cell death after IFNg treatment in 17 of 23 (~74%) IFNg-sensitive PDM lines covering all the MAPK mutant and triple wildtype molecular subtypes of melanoma...This pathway is active in all melanoma subtypes, making it an attractive target to enhance IFNg GI in tumor cells. Our results provide a new understanding of the IFNg GI pathway that will also be crucial to define mechanisms of GI resistance in tumor cells.
PD(L)-1 Biomarker • IO biomarker
|
JAK2 (Janus kinase 2) • IFNG (Interferon, gamma) • JAK1 (Janus Kinase 1) • MAPK1 (Mitogen-activated protein kinase 1) • STAT1 (Signal Transducer And Activator Of Transcription 1) • IFNAR2 (Interferon Alpha And Beta Receptor Subunit 2)
|
IFNG-L
|
ulixertinib (BVD-523)
2years
Release of IFN-γ by acute myeloid leukemia cells remodels bone marrow immune microenvironment by inducing regulatory T cells. (PubMed, Clin Cancer Res)
IFN-g release by AML cells induces an immune-regulatory program in MSCs and remodels BM immunological landscape toward Treg induction, contributing to an immunotolerant microenvironment.
Journal • IO biomarker
|
IFNG (Interferon, gamma)
|
IFNG-L • IDO1 expression • IFNG expression • IFNG elevation
over2years
CD8+CD69+ Expanded Tumor Infiltrating Lymphocytes from Soft Tissue Sarcoma Have Increased Tumor-Specific Functional Capacity (SITC 2021)
Conclusions TIL expanded from STS demonstrate greater tumor-specific functional capacity and cytotoxicity after CD8 enrichment and CD69+ FACS compared to bulk expanded TIL. These data validate the strategy to enhance CD8+CD69+ TIL during culture to yield a more efficacious cellular immunotherapy product.
Tumor-Infiltrating Lymphocyte
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD69 (CD69 Molecule) • IL2 (Interleukin 2) • GZMB (Granzyme B)
|
IFNG-L
over2years
Construction of Interferon-Gamma-Related Gene Signature to Characterize the Immune-Inflamed Phenotype of Glioblastoma and Predict Prognosis, Efficacy of Immunotherapy and Radiotherapy. (PubMed, Front Immunol)
Moreover, the IFNGrGS score had solid prognostic value and the potential to screen ICB and radiotherapy sensitive populations. Collectively, our study provided insights into the role of IFNG on the GBM immune microenvironment and offered feasible information for optimizing the treatment of GBM.
Clinical • Journal • Gene Signature • IO biomarker
|
EGFR (Epidermal growth factor receptor) • IFNG (Interferon, gamma) • IL10 (Interleukin 10) • TGFB1 (Transforming Growth Factor Beta 1) • IL4 (Interleukin 4) • TGFBI (Transforming Growth Factor Beta Induced)
|
EGFR mutation • IFNG-L
almost3years
[VIRTUAL] Single cell RNA sequencing of UTUC is feasible and reveals heterogeneity of the tumor and immune microenvironment (AUA 2021)
Our scRNA-seq data confirmed luminal subtype predominance and described the heterogeneous TME in UTUC. The statistically significant relationship of tumor cell IFNg with increased overall immune cell infiltration is notable and may have implications for systemic therapy response. Further high-resolution studies are needed to expand our knowledge of the molecular biology and TME of UTUC with implications for treatment selection and disease surveillance.
IFNG (Interferon, gamma) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C)
|
IFNG-L • IFNG expression